english.prescrire.org > Spotlight > Archives : 2020 > Drugs in 2019: therapeutic advances, compared with the previous 9 years

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2020 : 1 | 30 | 60

Drugs in 2019: therapeutic advances, compared with the previous 9 years

GRAPHICS From Prescrire's recap "Drugs in 2019: a brief review", graphics comparing the therapeutic advances during 2019 with the advances made in prior years, along with a table summarising Prescrire's ratings of new products and indications over the past 10 years. 

Therapeutic advances in 2019, compared with the previous 9 years
            Progrès notable Notable advance Pas de progrès No proven advantages
  Progrès minime Minimal advance Pas de progrès More dangerous than useful

See: "Drugs in 2019: a brief review" Prescrire Int 2020; 29 (214): 110-111. (Pdf, free).
 

Prescrire's ratings of new products and indications over the past 10 years: 2010-2018
 
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Bravo  BRAVO
0 0 0 0 1 0 0 0 0 0
A Real Advance  A REAL ADVANCE
1 0 1 0 2 3 1 1 2
1
Offers an advantage  OFFERS AN ADVANTAGE
3 3 3 6 5 5 5 9 11
10
Possibly helpful  POSSIBLY HELPFUL
22 13 14 12 15 15 9 18 22 13
Nothing new  NOTHING NEW
49 53 42 48 35 43 56 45 50 61
Judgement reserved  JUDGEMENT RESERVED
3 7 7 9 10 6 5 4 5
9
Not acceptable  NOT ACCEPTABLE
19 16 15 15 19 15 16 15 9
14
TOTAL 97 92 82 90 87 87 92 92 99 108
The year
in review
2010
(pdf)
2011
(pdf)
2012
(pdf)
2013
(pdf)
 2014
(pdf)
2015
(pdf)
2016
(pdf)
2017
(pdf)
2018
(pdf)

2019
(pdf)


See: 
"Drugs in 2019: a brief review" Prescrire Int 2020; 29 (214): 110-111. (Pdf, free).

 A REAL ADVANCE
  • emicizumab in patients with haemophilia A and factor VIII inhibitors (Prescrire Int n° 210).
 OFFERS AN ADVANTAGE
  • chenodeoxycholic acid in cerebrotendinous xanthomatosis (Prescrire Int n° 207);
    glecaprevir + pibrentasvir for adolescents with chronic hepatitis C (Rev Prescrire n° 434);
  • axicabtagene ciloleucel in certain types of lymphoma when other treatment options have been exhausted (Prescrire Int n° 208);
  • durvalumab as "maintenance" treatment in lung cancer (Prescrire Int n° 212);
  • pembrolizumab in combination with cytotoxic drugs in lung cancers when a small proportion of tumour cells express the PD-L1 protein (Prescrire Int n° 212);
  • raltegravir granules for neonates with HIV infection (Rev Prescrire n° 431);
  • ruxolitinib in myelofibrosis (Prescrire Int n° 205);
  • tisagenlecleucel for children and young adults with certain types of acute lymphoblastic leukaemia (Prescrire Int n° 208);
  • trastuzumab emtansine in inoperable breast cancer (Prescrire Int n° 207);
  • trientine in Wilson's disease (Prescrire Int n° 214)
 POSSIBLY HELPFUL 
  • emtricitabine + tenofovir disoproxil for prevention of HIV infection in adolescents (Prescrire Int n° 206);
  • atazanavir oral powder for patients from 3 months of age with HIV infection (Prescrire Int n° 207);
  • baclofen in alcohol dependence (Prescrire Int n° 212);
  • cenegermin eye drops in neurotrophic keratitis (Prescrire Int n° 204);
  • colchicine in acute pericarditis (Prescrire Int n° 211);
  • dupilumab in adults with atopic eczema (Prescrire Int n° 204);
  • erenumab for prevention of migraine attacks (Prescrire Int n° 207);
  • glycopyrronium for sialorrhoea due to neurological disorders (Rev Prescrire n° 430);
  • metreleptin in lipodystrophy with leptin deficiency (Rev Prescrire n° 434);
  • pasireotide for intramuscular use in Cushing's disease (Rev Prescrire n° 425);
  • peginterferon alfa-2a for patients from 3 years of age with chronic hepatitis B (Rev Prescrire n° 423);
  • glycerol phenylbutyrate in urea cycle disorders (Rev Prescrire n° 428);
  • tocilizumab for subcutaneous use in giant cell arteritis (Prescrire Int n° 205).
 JUDGMENT RESERVED
  • adalimumab in children with chronic anterior uveitis (Rev Prescrire n° 429);
  • brentuximab vedotin in cutaneous T-cell lymphoma (Rev Prescrire n° 426);
  • burosumab in X-linked hypophosphataemia (Prescrire Int n° 206);
  • cerliponase alfa in neuronal ceroid lipofuscinosis type 2 (Prescrire Int n° 213);
  • darvadstrocel for complex perianal fistulae in Crohn's disease (Prescrire Int n° 213);
  • mogamulizumab in mycosis fungoides and Sézary syndrome (Rev Prescrire n° 434);
  • oxycodone + naloxone in restless legs syndrome (Prescrire Int n° 205);
  • sirolimus in sporadic lymphangioleiomyomatosis (Prescrire Int n° 212);
  • tocilizumab in cytokine release syndrome due to CAR T-cell therapy (Rev Prescrire n° 428).
 NOT ACCEPTABLE 
  • abemaciclib in certain types of breast cancer (Rev Prescrire n° 431);
  • colchicine + opium + tiemonium in acute pericarditis (Prescrire Int n° 211);
  • ataluren for children aged 2 to 4 years with Duchenne muscular dystrophy (Prescrire Int n° 213);
  • chondroitin 1200 mg oral gel in sachets (Rev Prescrire n° 424);
  • ertugliflozin in type 2 diabetes (Prescrire Int n° 213);
  • ethinylestradiol + dienogest for contraception or acne (Rev Prescrire n° 426);
  • recombinant human parathyroid hormone in chronic hypoparathyroidism (Prescrire Int n° 210);
  • mepolizumab for patients from 6 years of age with severe asthma (Prescrire Int n° 211);
  • olaparib in ovarian cancer without a BRCA mutation (Prescrire Int n° 209);
  • pentosan polysulfate in bladder pain syndrome (Prescrire Int n° 204);
  • pertuzumab as adjuvant treatment for certain types of breast cancer at high risk of recurrence (Prescrire Int n° 210);
  • solifenacin oral solution in neurogenic detrusor overactivity in children (Rev Prescrire n° 429);
  • tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat for children with HIV infection (Prescrire Int n° 206);
  • tolvaptan in polycystic kidney disease with severe renal failure (Rev Prescrire n° 431).

©Prescrire 1 April 2020

"Drugs in 2019: a brief review" Prescrire Int 2020; 29 (214): 110-111. (Pdf, free).

Share Share on Facebook Share on Twitter

 

Share
Partager sur Facebook Partager sur Twitter

 
Download the full review.
Pdf, free

For more information:

Drugs in 2019:
a brief review
(April 2020)
Free

See also:

The Prescrire Drug
Awards for 2019
(February 2020)
Free

Prescrire's Drug
ratings
(February 2020)
Free